Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma

Lenvatinib is a first-line standard treatment for advanced hepatocellular carcinoma (HCC) with better anti-tumor effects than sorafenib, as shown by greater inhibition of the kinases of fibroblast growth factor receptor and vascular endothelial growth factor (VEGF) receptor. This report describes a...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Naomi, Tajiri, Kazuto, Futsukaichi, Yuka, Tanaka, Shinichi, Murayama, Aiko, Entani, Toshiki, Kobayashi, Saito, Takahashi, Kosuke, Fujii, Tsutomu, Imura, Johji, Yasuda, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036537/
https://www.ncbi.nlm.nih.gov/pubmed/32110202
http://dx.doi.org/10.1159/000505774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036537/
https://www.ncbi.nlm.nih.gov/pubmed/32110202
http://dx.doi.org/10.1159/000505774

Ejemplares similares